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Table 1. Major laboratory parameters of the index patient.
Day 1 Day 11 Day 35
White blood count ( 109) 27.95 10.77 10.13
Differential leucocyte
count (%)
N78.1, L20.8,
M0.2, E0.4
N78.7, LI6.5,
M4.4, E0
N70.6, L21.5,
M6.7, E1.1
Hemoglobin (g/L) 98 92 85
Platelet ( 109) 258 163 154
Bilirubin (mmol/L) 17.7 6.8 6.6
Bilirubin(conjugated)
(mmol/L)
6.1 4 3.9
Protein (g/L) 54.6 46.5 57.3
Albumin (g/L) 28 25.4 28.6
Aspartate
aminotransferase (U/L)
77 13 16
Alanine
aminotransferase (U/L)
378 31 31
Alkaline phosphatase (U/L) 261 83 62
Gamma-glutamyl
transpeptidase (U/L)
129 62 43
Serum urea (mmol/L) 42.8 26.9 17.16
Serum creatinine (mmol/L) 1336 551 387
Urinary protein
excretion (g/d)
1.511 1.299 1.009
Red blood cells per
high-power field
1.27 1.65 282
White blood cells per
high-power field
15.69 6.75 3.25
Epithelial cells per
high-power field
17.82 1.05 0.53
Specific gravity of urine 1.010 1.012 1.006
Urinary osmotic pressure
(mOsm/kg H2O)
409 483 261
N, neutrophil; L, lymphocyte; E, eosinophil; M, monocyte.
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(n Z 23).
Age, years 73.1 5.1
Gender, male / female 8 / 15
Body weight, kg 63.1 12.3
Hypertension, n (%) 17 (77.3%)
Diabetes mellitus, n (%) 2 (8.7%)
Charlson’s Comorbidity Index score 4.6 1.7
Diagnosis, n (%)
Minimal change nephropathy 4 (17.4%)
Primary focal segmental glomerulosclerosis 3 (13.0%)
IgA nephropathy 1 (4.3%)
Lupus nephritis 2 (8.7%)
Crescentic glomerulonephritis 5 (21.7%)
Post-infectious glomerulonephritis 1 (4.3%)
Membranous nephropathy 7 (30.4%)
Immunosuppressant, n (%)
Steroid 23 (100%)
Cyclosporin 7 (30.4%)
Mycophenolate mofetil 2 (8.7%)
Cyclophosphamide 4 (17.4%)0275
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Objective: To assess the changing prevalence of idiopathic membranous ne-
phropathy (iMN) in Chinese patients undergoing renal biopsy from our
nephrology center.
Methods: The records of 8559 consecutive native renal biopsies performed in
adults (14 years of age) in the First Affiliated Hospital of Zhejiang Univer-
sity between 2005 and 2014 were retrospectively analysed. The criteria for
renal biopsy and pathologic diagnosis were kept unchanged. The patients
were grouped according to a 5-year interval, 2005e2010 (period 1),
2010e2014 (period 2), and divided into four age groups (14e24, 25e44,
45e59,  60 years old).
Results: Among 8559 specimens, 6336 (74.03%) were diagnosed as primary
glomerular diseases (PGD). IgA nephropathy (IgAN) was the most common
PGD (55.67%), with a significant decrease in the period 2 (50.82% vs.
64.79%, P < 0.001). The prevalence of iMN in PGD increased rapidly
from 16.59% in period 1 to 25.21% in period 2 in all groups of age (P <
0.001). In patients aged 45e59 years, the proportion of renal histopathol-
ogy stage I and stage II of iMN in PGD was significantly higher in period 2
than in period 1 (20.54% vs. 30.29%, P < 0.001). 51.08% of petients with
iMN presented with nephrotic syndrome, the remainder presented with
chronic nephritis syndrome (28.11%) and asymptomatic urinary abnormal-
ity (20.81%). There were no significant differences in clinical characteris-
tics including age, gender, hypertension, serum cholesterol, serum
albumin and glomerular filtration rate between the two periods (P >
0.05).Conclusion: The prevalence of iMN in PGD in our nephrology center has
increased significantly over the past 10 years. The increase of adult iMN is
mainly due to the increase in the early stages of iMN in middle-aged patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.0310278
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Objective: Glomerulonephritis is not uncommon among elderly and immuno-
suppressive treatment is often needed to achieve remission. Compared to
young patients, elderly might bear higher complication risks especially infec-
tion. We looked into the adverse events among elderly who received immu-
nosuppressive therapy.
Methods: We retrospectively reviewed all elderly (age 65 years) who under-
went renal biopsy at our institution between 2007 and 2014. Patients diagnosed
to have glomerulonephritis were included. Their baseline demographics, diag-
nosis, immunosuppressants received, details of infection-related hospitaliza-
tion, other clinical outcomes including treatment response, development
into end-stage renal disease (ESRD) or death were retrieved.
Results: 27 patients were identified and 23 of them had received immuno-
suppressants. Their total follow-up duration was 764.4 patient-months,
which included 450.8 patient-months of immunosuppressive treatment.
Baseline demographics, treatment details, infectious complications and
other clinical outcomes of the cohort are shown in Table 1. During follow-
up, there were 60 hospitalizations, among which 25 episodes (41.7%) were
due to infections involving 12 patients (51.2%). Overall infection-related hos-
pitalization rate was once every 30.6 patient-months (i.e. 0.39 episodes per
year). Among the 12 patients, median onset of infection was 3.2 months (IQR
1.6e45.3) after starting immunosuppressants. Eventually, 4 patients (17.4%)
progressed to ESRD and 5 patients (21.7%) died. 60% mortality was attributed
to infections. Comparing patients with and without infections, patients
complicated with infections had lower body weight, higher baseline serum
creatinine and more non-responders to treatment (Table 2). Binary logistic
regression confirmed non-responder (OR 10.5, 95% CI 1.4e81.1, p Z 0.02)
as the only independent risk factor for infectious complications.
Conclusion: Immunosuppressive treatment is associated with infectious
complication risks among elderly suffering from glomerulonephritis. Patients
with poor clinical response are particularly prone to developing infections.
Over-aggressive treatment should be avoided in this high-risk group in order
to minimize infection risks and mortality.
Table 2. Comparison between patients with and without infectious
complications.
Parameters With infections
(n Z 12)
Without
infections
(n Z 11)
P value
Age, years 74.8 5.1 71.3 4.1 0.10a
Male gender, n (%) 3 (25%) 5 (45.5%) 0.40b
Body weight, kg 57.2 12.7 68.5 9.5 0.03a
Hypertension, n (%) 8 (72.7%) 9 (81.8%) 1.00b
Diabetes mellitus, n (%) 2 (16.7%) 0 (0%) 0.48b
Charlson’s Comorbidity
Index score
5.1 1.9 4.1 1.3 0.16a
Baseline serum
creatinine, umol/L
234 (94e545) 116 (57e161) 0.04c
Baseline urine creatinine
clearance, mL/min
23.3 (10.9e57.8) 48 (29e72) 0.10c
Baseline serum albumin, g/L 25 (17e32) 22 (20e24) 0.57c
Non-responder, n (%) 9 (75%) 2 (18.2%) 0.01b
Continuous data is expressed as mean standard deviation or median
(interquartile range)
aComparison by independent sample t test
bComparison by Fisher’s exact test
cComparison by Mann-Whitney test
Azathioprine 5 (21.7%)
Duration on immunosuppressant, months 13.7 (5.7e30.7)
Non-responder to immunosuppressant) 11 (47.8%)
Hospitalization, episodes (days)
Infection-related
Pneumonia 8 (34)
Urinary tract infection 4 (20)
CMV disease 2 (23)
Septicaemia of uncertain origin 4 (284)
Other infections 7 (30)
Cardiovascular / cerebrovascular events 4 (109)
Others 31 (144)
End of follow-up status, n (%)
End-stage kidney disease 4 (17.4%)
Death 5 (21.7%)
Proportion of mortality attributed to infection 3 (60%)
Continuous data expressed as mean standard deviation or median
(interquartile range); CMV Z cytomegalovirus.
)Defined as deteriorating renal function or reduction in proteinuria
<50% from baseline.
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Methods: Sixty-eight IMNpatientswereenrolled inthisprospectivecohort study.
Low dose prednisone and low dose cyclosporine were prescribed on the basis of
renin-angiotensin-aldosterone (RAS) inhibition. Remission rate, relapse rateand
different renal functionchangeprofileswere recorded.Followuprenal endpoint
was defined as a decrease in eGFR >50% from baseline and a development of
eGFR< 60 ml/min/1.73 m2. Risk factors for renal injury were further analysed.
Results: A cyclosporine dose of 2.0 0.5 mg/kg/d and prednisone of
0.33 0.18 mg/kg/d were prescribed. The duration of cyclosporinetreatment was 31 17 months. The follow-up time was 46 20 months.
Twenty-nine patients (43%) achieved complete remission at 15.9 11.8
months, and 33 patients (47%) got partial remission at a median of 6 (range:
1e40) months. Twenty-six out of 62 patients (42%) with remission had relapse.
Fourteen patients (20%) developed cyclosporine-acute renal injury (CsA-ARI)
at 2.5 0.8 months, with SCr increased by > 30% during the first 3 months,
and 16 patients (24%) developed cyclosporine-chronic renal injury (CsA-CRI)
at 7.1 3.0 months with SCr increased by > 30% or eGFR decreased by >
30% during the course of the first year. Proteinuria at the time of CsA-ARI
was indentified as an independent risk factor for CsA-ARI. Lower baseline
eGFR level was identified as independent risk factor for CsA-CRI. At the end
of follow up, 16 patients (24%) reached the renal endpoint. Presence of
intimal fibrosis of artery and higher time-averaged proteinuria were identified
as independent risk factors for renal endpoint. RAS inhibition treatment
decreased the risk of renal endpoint. Neither cyclosporine cumulative usage
time nor cumulative dosage was found to be risk factors for renal injury.
Conclusion: Low dose cyclosporinewas effective in treating nephrotic patients
of IMN. Cyclosporine-associated renal injury should be an important concern
even at this low implemented dosage, especially in lower initial eGFR patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.0330305
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Objective: Insulin-like growth factor I (IGF-I) and insulin-like growth factor II
(IGF-II) are polypeptides regulating growth and cellular proliferation in
humans, and most importantly influence renal parenchyma cells and endo-
thelial cells. IGF-binding protein 3 (IGFBP-3) and IGF-binding protein 5
(IGFBP-5) modify the function of IGFs by binding to them with high-affinity.
This study aimed to investigate the role of IGF-I, IGF-II, IGFBP-3 and IGFBP-5
in adult Henoch-Schoenlein nephritis.
Methods: Serum levels of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were measured
by ELISA in 50 healthy controls (control group) and 85 adult patients with
Henoch-Schoenlein purpura (HSP group) in which 52 patients with HSPN
(HSPN group) were included. The clinical features, laboratory data and renal
pathological findings of candidates were also analyzed.
Results: Compared to the controls, plasma albumin was significantly
decreased yet serum levels of IgA and IgA/C3 were increased in the HSP
group. The serum levels of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were signifi-
cantly increased in HSP group compared to the control group (P < 0.001). Pa-
tients with HSPN had higher levels of IGF-I, IGF-IIand IGFBP-3 than HSP
patients without renal damage. In patients with HSP, the serum levels of
IGF-I, IGF-II and IGFBP-3 were related to proteinuria and plasma albumin
positively, and estimated glomerular filtration rate (eGFR) negatively by cor-
relation analysis. Logistic regression modeling confirmed that levels of IGF-I,
IGF-II and IGFBP-3 were positively related to proteinuria after adjustment
for age, albumin and eGFR. By a mean of 42.4 months of follow-up, serum
levels of IGF-I, IGF-II and IGFBP-3 were risk factors for 30% decline in eGFR.
Conclusion: The serum levels of IGF-I, IGF-II and IGFBP-3 could be new
markers to evaluate proteinuria and predict the renal outcomes in adult HSPN.http://dx.doi.org/10.1016/j.hkjn.2015.09.0350306
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The direct renin inhibitor aliskiren displays antihypertensive and antialbu-
minuric effects in humans and in animal models. Emerging evidence has
shown that aliskiren localizes and persists in medullary collecting ducts even
after treatment was discontinued. The purpose of the present study was to
